Website Here

If you have an idea for a business and need a bit of cash to get started or you’re running a small business and need up to £500 to buy equipment, promotion flyers, hardware etc, you can apply.

Apply for between £50 and £5000 and once you receive the money, the only thing we ask is you agree to be profiled on the site so we can see how you’re getting on. The money doesn’t have to be paid back; it’s for you to use on your idea or business.

Apply via clicking the button below and outline how much money you need and for what purpose. Make a good case for your idea and then encourage as many people as possible to vote for you. The number of votes required is equal to the amount of funding you’re looking for so to obtain £500 you’ll need to secure 500 virtual votes.

Remember, the Enterprise Nation community will help you spend the dosh! Want to use it to buy a camera to take good pictures of your products? Ask peers about the best deal on the market. Want to spend the money on a Google Adwords campaign but not sure where to start? Watch our video clips that will show you how!

All the support you need is right here so you can access the money you need and keep coming back to pick up tips, access content and pose questions in our friendly forums.

For Assistance with Business Plannign and Fundraising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Full Text Here

A new Technology Strategy Board scheme is offering funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.

Open from 4 April 2011, the Grant for Research and Development (Grant for R&D) scheme will support R&D projects which offer potentially significant rewards and could stimulate UK economic growth. In contrast to the Collaborative R&D programme, Grant for R&D funding is available to single companies.

Three types of grant are available:

• Proof of market
• Proof of concept
• Development of prototype

Any UK SME working in any sector may apply; applications are accepted on a rolling basis for assessment by independent experts.

Grant for R&D replaces the scheme previously offered by regional development agencies. The new scheme will work alongside existing programmes in Scotland, Wales and Northern Ireland.

For Assistance with Preparing Business Plans for Fund Raising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Full Text Report

BBC has published an article on this extra cash for science

The bulk of the funds (£80m), which come from the bank levy, will be invested in new research centres at Daresbury, Norwich and Cambridge, he said.

The smaller proportion (£20m) would go to projects at Harwell.

These include investments in new space technologies, and in three new instruments at the Isis neutron source.

Isis is a giant machine that can probe the structure of matter. Scientists exploit its insights to advance a host of new technologies from drug design to improved mobile phones.

Also included in the budget was a promise to address regulatory issues that are deemed to impede science-based industries from maximising their performance.

In the life sciences, Mr Osborne announced a new health research regulatory agency that would aim to simplify and speed up the business of running the clinical trials which are essential to the development of new drugs.

For Assistance with Fundraising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Full Text Here

The Bupa Foundation is an independent medical research charity

AIMS

The charitable objects (intentions) expressed above are interpreted in the aims to fund:

1. Implementation of translational and action orientated research-based solutions, which: :
   • Drive tangible action to prevent or alleviate chronic disease or the adverse elements of ageing; and to promote wellbeing and/or
   • Lead to the sustained uptake of healthy lifestyles and/or
   • Measurably improve public health to a significant degree

AND/OR

2. Research which leads to the development of such solutions.

OBJECTIVES

The Foundation’s objectives are:
To offer grants to implement research-based solutions, in any of the following areas, which reflect global challenges in public health:

1. Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace or educational establishments;
2. Utilising or developing shared-decision making tools for better patient decisions for use amongst disadvantaged or diverse groups;
3. Promoting and encouraging healthy ageing through physical activity and other behaviour-based and social solutions for the older age group (65+ years);
4. Using new technologies to organise and interpret health outcomes data cheaply and effectively – for better design of community health activities and to improve patient decision making.

All projects should develop, apply or test research-based approaches in community settings – with clear intended impacts on public health.

The Bupa Foundation supports high quality medical research through its four programmes:

Programme 1: Research grants (all four objectives above)

In 2011 the first round under the new funding strategy will be held in June 2011. The closing date for this round is 31 March 2011. This may change in future years.

All projects funded under this heading should develop, apply or test research-based approaches in community settings – with clear intended impacts on public health.

The areas for funding as detailed above are not intended to be exclusive of each other.

Research grant applications are open only to clinicians, researchers and health care professionals who are UK residents. Applicants are encouraged to include on their application partnerships with other universities, healthcare organisations, research institutes, charities and community groups

The Foundation will normally consider applications for funding to a maximum of £100,000 per annum for up to three years term. Successful applications are more likely if added value (such as potential for co-funding) is clearly demonstrated.

If funding is required for a longer period a separate application must be made in the third year. Continuing support cannot be guaranteed; any application for further funding will be considered in open competition with other applications submitted on that occasion.

Programme 2: Annual Multi-country Grant

A total grant of up to £600,000 will be awarded to fund one multi-country* initiative of 1 to 3 years duration, under the first funding theme on sustained behaviour changes

“Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace or educational establishments”"

*This should be defined as a project carried out in at least two of the following countries: United Kingdom, Spain, Australia, New Zealand, the United States or India

It will be advertised on the Bupa Foundation web site and appropriate online journals.

In 2011 it will be judged in September, with a closing date of 20 June 2011.

This time table may change in future years.

Programme 3: Philip Poole-Wilson Seed Corn Fund

A fund of £200,000 per annum to award grants of up to £20,000 each, to fund research into any of the four Research Grant themes.

Each application must be made either by a researcher beginning their research career or if a pilot project by an experienced researcher, must include such a researcher on the team and contribute meaningfully to his/her development and training. High priority will be given to applications from young and/or new researchers who have not previously been funded.

Philip Poole-Wilson Seed Corn fund grant applications are open only to clinicians, researchers and health care professionals who are UK residents Applicants are encouraged to include on their application partnerships with other universities, healthcare organisations, research institutes, charities and community groups

This grant round will be held in November each year, with a closing date of 31 July.

Programme 4: Annual Prizes

£60,000 will be allocated for completed research and/or development that has been conducted over the past 3 years into each of the four Research themes; -

1. Healthy Lives Prize

Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace

2. Patients as Partners Prize

Utilising or developing shared-decision making tools for better patient decisions for use amongst disadvantaged or diverse groups;

3. Vitality for Life Prize

Promoting and encouraging healthy ageing through physical activity and other behaviour-based and social solutions for the older age groups (65+ years)

4. Technology for Healthy Outcomes Prize

Using new technologies to organise and interpret health outcomes data cheaply and effectively for better design of community health activities and improved patient decision making.

Foundation Prizes will focus on recognition of excellent work by aspiring and promising new researchers in the early phases of their career.

Foundation Prizes are advertised in January/February each year, with a closing date in early July. Full details of Awards entry criteria and the application process can be found at: http://www.bupafoundation.co.uk/asp/awards/eligibility.asp.

The Chairman and Board of Governors of the Bupa Foundation reserve the right to amend and/or add to Programme details as they consider appropriate, at any future date.

For Assistance with Grant Funding and Business Planning Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Colleagues – I thought this may be of interest to you?

AngelNews, an online news service for entrepreneurs and investors is inviting you to pitch at its launch events of Pitching for Management in Leeds and Sheffield at NO CHARGE.

These events allow entrepreneurial people like you to pitch to rooms full of senior executives to join your teams in exchange for sweat equity, commission and/or salary.  Pitching for Management has been running in London since January 2009 and has started rolling out throughout the UK.

Typically audience members have worked with fast-growth companies in the past and have a wealth of experience in roles ranging from sales, marketing and finance directors, to mentors, non-executives directors and CEO’s.

So if you need a sales director who will help you build revenue, an FD who will look after the money side of things or even a chairman or NED who will help you fulfill its overall potential, you can come and pitch for them for free.  (Whatever your stage of business)

Pitching for Management offers great exposure to a high-calibre audience and hopefully you will find that perfect person you’ve been looking for.

If this sounds of interest to you, call Michelle Williams of AngelNews on 01761 452248 or email michelle@angelnews.co.uk.   She will be happy to talk through the concept with you.

Pitching for Management is taking place in Leeds on 31^st March and Sheffield on 12^th April.

We are holding a similar event in Manchester on 30^th March.

For Assistance with Business Planning and Fund Raising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Deputy Prime Minister Nick Clegg has announced that a second bidding round of the Regional Growth Fund will open on 12 April 2011.

The Government announced in the 2010 Budget, that it would commit itself to create a Regional Growth Fund (RGF). Launched as part of the publication of the Coalition Government’s Local Growth: Realising Every Place’s Potential White Paper, the Fund completed its first round earlier this year.

The RGF is a discretionary £1.4 billion Fund that will operate for three years between 2011 and 2014 to achieve its two main objectives of:

• stimulating enterprise by providing support for projects and programmes with significant potential for creating long-term private sector led economic growth and employment; and
• helping those areas and communities that are currently dependent on the public sector make the transition to sustainable private sector-led growth and prosperity.

The Fund subsequently encourages private sector enterprise, including social enterprise, to create opportunities for people and places to adjust to reductions in public spending, and enable private sector investors, business, the public sector and communities to come together with an overall strategy for their area.

Bids for funding from private bodies and public-private partnerships across England on a challenge basis are welcomed; however, the minimum amount of grant that can be applied for is £1 million.

Ministers are currently considering increasing the amount of funding available in the first round of bidding to the Regional Growth Fund as the Government prepares to announce which projects will benefit.

Deputy Prime Minister Nick Clegg made the announcement of the second round during a summit for local enterprise partnerships in Coventry. He said the successful first round bids to the Fund would be made public “shortly” and that the number of high quality bids received had led the Government to consider whether to increase the share of the £1.4 billion overall Fund available in the initial round.

Round two will open to applications on 12 April 2011.

Further details of the Fund are available online at the BIS website (opens in new window).

For Assistance with Fund Raising and Commercialisation Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Full Text Here

The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of FDA’s Office of Orphan Products Development (OPD) grant program. The goal of FDA’s OPD grant  program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA  provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the  application’s Background and Significance section documentation to support the estimated prevalence of the orphan disease or condition (or in the case of a vaccine or diagnostic, information to support the  estimates of how many people will be administered the diagnostic or vaccine annually) and an explanation of how the proposed study will either help support product approval or provide essential data needed
for product development.

For an Orphan Regulatory Expert EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Full Text Here

Funding is open to academic and industry researchers through the Foundation’s Pipeline Programs, which consist of three annually recurring initiatives, known collectively as The Edmond J. Safra Core Programs for PD Research, as well as the industry-exclusive Therapeutics Development Initiative. The Foundation seeks investigator-initiated proposals focused on the following critical points along the translational pathway to new therapies for Parkinson’s disease:

• Testing Novel Hypotheses: Quick support for high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD.
• Validating Novel Targets: Support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies.
• Catalyzing and Expanding Preclinical Development: Industry-exclusive support for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
• Clinically Testing Novel Therapies: Support for clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD.

“The Pipeline Programs are a core element of our Foundation’s efforts to drive research that will speed therapeutic development at historically under-funded points on the pipeline,” said Todd Sherer, the Foundation’s acting CEO. “The programs are part of MJFF’s progressive work to keep the most promising and significant projects moving forward toward notably improving quality of life for patients now and in the future.”

Brief program descriptions follow. Full details are available at www.michaeljfox.org/research.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Published by Rodman and Renshaw and EpstineBeckerGreen full Text Here

Based on interviews with over 75 healthcare investors in the US, this report offers valuable insight into emerging trends in investment activity, as well as a detailed forecast for specific subsectors, including biotechnology and pharmaceuticals; medical devices; healthcare providers and payors; and healthcare services.

Respondents to this survey unanimously agree that healthcare M&A activity will either increase or remain at its current level over the next 12 months. The biotechnology and pharmaceuticals subsector and the healthcare services subsector are particularly likely to witness a significant increase in M&A during this time, according to 87% and 83% of respondents, respectively.

Investment patterns are likely to vary according to industry over the next 12 months. Strategic buyers are likely to be most active in the biotechnology and pharmaceuticals subsector, following on a recent wave of large-cap deals including the US$68bn Pfizer-Wyeth merger and the US$44bn Roche-Genentech merger. Financial buyers, on the other hand, are likely to focus their attention on the healthcare services space, where recent private equity buyouts include TPG Capital’s US$5.3bn acquisition of IMS Health.

Click Here for Business Planning Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

This guidance provides information on the implementation of section 1102 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), which adds new section 524 to the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360n). Section 524 authorizes FDA to award priority review vouchers to sponsors of certain tropical disease product applications that meet the criteria specified by the Act. A priority review voucher may be used by the sponsor who obtains it or another sponsor to obtain a priority review for a different application. A priority review voucher may be transferred from the sponsor who obtains it to another sponsor.

These vouchers are valued at between US$50 and US$300 million, and there is grant money available to fund development it is a great way of generating large anounts of value whilst saving lives.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”